Medication Reconciliation After Heart Failure Discharge

Learning objectives#

• Reconcile medicines by comparing intent, records, dispensing, and actual use rather than accepting any single list as truth.
• Distinguish recurrent congestion from excessive decongestion, medication effect, kidney injury, electrolyte disturbance, and other post-discharge threats.
• Link each heart-failure medicine to its indication, duplication hazards, contraindications, and required monitoring.
• Build a time-bound plan for volume assessment, blood pressure, kidney function, sodium, potassium, symptoms, and follow-up after discharge.
• Use teach-back, pharmacy coordination, and explicit task ownership to close transition gaps.
• Recognize when outpatient reconciliation must stop and urgent or emergency assessment must begin.

Initial presentation#

A 76-year-old woman is seen in primary care four days after a hospitalization for worsening heart failure. During admission she received intravenous diuresis, and echocardiography showed a left ventricular ejection fraction of 30 percent. The hospital team documented heart failure with reduced ejection fraction and changed several medicines before discharge.

Her daughter scheduled the visit because the patient felt lightheaded when standing that morning and was unsure which bottles to use. She has poor appetite, mild nausea, and less urine than yesterday. Her breathing and ankle swelling are better than before admission. She can sleep flat and denies chest pressure, new palpitations, or fainting. She denies fever, unilateral leg swelling, or focal neurologic symptoms.

The electronic discharge list contains a loop diuretic at a higher frequency than before admission, a newly started angiotensin receptor-neprilysin inhibitor, a beta blocker, a newly started mineralocorticoid receptor antagonist, and a sodium-glucose cotransporter-2 inhibitor. It also still displays her prior angiotensin-converting enzyme inhibitor under a section labeled "continue home medicines." A potassium supplement remains on the primary-care list from a much older diuretic regimen.

The patient's pill organizer contains both the old angiotensin-converting enzyme inhibitor and the new angiotensin receptor-neprilysin inhibitor. She has taken both since discharge because the after-visit summary listed both. She also resumed the potassium supplement and takes an over-the-counter anti-inflammatory medicine for knee pain. One bottle has two different instruction labels layered on top of each other. The community pharmacy received discontinuation messages for only some of the old medicines.

At discharge her weight was 68 kilograms. Her home scale showed 66.5 kilograms this morning, although the scale sits on carpet and was not checked against another device. In clinic, seated blood pressure is 94/58 mm Hg and pulse 64 per minute. On standing she becomes lightheaded; pressure is 84/52. Oxygen saturation is normal, neck veins are not visibly elevated, lungs are clear, and there is no peripheral edema. Extremities are warm. She is alert but has difficulty hearing soft speech. A chemistry panel was ordered for "next week," but no laboratory appointment or responsible clinician is named.

Problem representation#

This is an older adult four days after decongestion for newly recognized HFrEF who now has symptomatic postural hypotension, reduced intake and urine, and further weight loss. There is no clear evidence of recurrent congestion, and there are several high-consequence medication discrepancies: overlapping renin-angiotensin system therapies, an unreconciled potassium supplement, and an over-the-counter anti-inflammatory medicine. The discrepancies also include conflicting diuretic instructions and no closed-loop laboratory plan.

The safest working model is a hazardous transition with possible excessive volume reduction, drug-related hypotension, acute kidney dysfunction, and hyperkalemia until proved otherwise. Evidence-based heart-failure therapy remains important, but rapid initiation does not mean every medicine is tolerated in every combination without monitoring. The patient needs same-day assessment and discrepancy resolution, not a routine refill visit.

Prioritized differential#

1. Medication-related hypotension and kidney or potassium injury#

Reasoning for: The patient is taking two therapies that were not intended to overlap, plus a mineralocorticoid receptor antagonist, potassium supplement, loop diuretic, and anti-inflammatory medicine. She has symptomatic low standing pressure, reduced intake, and reduced urine. This combination can alter perfusion, kidney function, and potassium balance.

Reasoning against or still uncertain: No laboratory result is yet available, and a modest creatinine change can occur during decongestion or initiation of disease-modifying treatment. The degree, trajectory, volume state, and potassium level determine significance. The adverse effect hypothesis must be tested urgently rather than assumed.

2. Excessive decongestion or intravascular volume depletion#

Her congestion improved, weight continued to fall, intake is poor, examination is dry, and postural symptoms are present. Those findings support overdiuresis or low effective circulating volume. However, examination and weight are imperfect, and heart failure can involve congestion without dramatic edema. The team must avoid treating one home-scale number in isolation.

3. Recurrent or residual heart-failure congestion#

Early recurrence after hospitalization is common and cannot be dismissed. Worsening orthopnea, breathlessness, or edema would support this branch. So would abdominal fullness, rising jugular venous pressure, or pulmonary crackles. So would weight gain or hypoxemia. In this case, symptoms and examination argue against congestion as the main cause today, but the recent hospitalization keeps it in view.

4. Arrhythmia, ischemia, or another cardiac complication#

Bradyarrhythmia, tachyarrhythmia, acute coronary syndrome, or low-output physiology can produce weakness. Any of them can produce hypotension or kidney dysfunction. The current regular pulse, warm extremities, and absence of chest symptoms lower but do not eliminate concern. Syncope, ischemic symptoms, or new ECG change would escalate this branch. So would cool extremities, confusion, or persistent hypotension.

5. Infection, bleeding, thromboembolism, obstruction, or another acute illness#

Post-discharge decline may reflect infection, gastrointestinal bleeding, or pulmonary embolism rather than heart-failure therapy alone. It may reflect urinary obstruction, poor oral intake, or an unrelated illness. Fever, bleeding, and hypoxemia help redirect the workup. So do unilateral swelling, abdominal or flank symptoms, and severe diarrhea or vomiting. So does a complete blood count or urinalysis when indicated.

6. Measurement or documentation error without physiologic injury#

The carpeted scale, duplicated instructions, and copied electronic lists demonstrate information-quality problems. Yet a data error cannot explain away reproduced symptomatic hypotension or reduced urine. System defects and physiologic harm can coexist.

Focused history and examination#

Reconstruct the hospitalization and intended regimen#

The clinician obtains the discharge summary, final inpatient medication-administration record, and cardiology plan. The clinician obtains discharge prescriptions and pending results. The clinician also obtains documented reasons for starting, stopping, or changing each medicine. The team confirms whether the ejection fraction and hemodynamic state support the HFrEF pathway, what precipitated the admission, whether kidney function and potassium were stable at discharge, and whether the patient received the final instructions after the last medicine changes.

Build the best possible medication history#

The patient and daughter place every prescription bottle, nonprescription product, and supplement on the table. Every inhaler, patch, and as-needed medicine goes there too. For each, the team records name, strength, and actual amount taken. It records timing, indication, and prescriber. It records last dose, refill source, and what the patient believes it does. Pharmacy fill records and the preadmission primary-care list are compared with the inpatient and discharge lists. A discrepancy is not considered resolved until the intended action and responsible prescriber are known.

The clinician specifically asks about anti-inflammatory pain medicines, potassium-containing salt substitutes, and herbal products. The questions cover decongestants, missed doses, and duplicated bottles. They cover pillbox filling, affordability, and swallowing. They cover vision, hearing, cognition, and who can help. "Resume home medicines" is not accepted as a safe instruction.

Assess physiology, not only the list#

History covers breathlessness at rest and exertion, orthopnea, and nighttime awakening. It covers edema, abdominal fullness, and appetite. It covers thirst, vomiting or diarrhea, and urine output. It covers weight trend, dizziness, falls, and fainting. It covers chest symptoms, palpitations, and bleeding. It covers fever and medication adverse effects. The examination repeats blood pressure and pulse with symptoms. It evaluates perfusion and mentation, jugular venous pressure, and lungs. It evaluates cardiac rhythm, edema, abdomen, and evidence of infection or bleeding. Weight is measured on a calibrated clinic scale and compared cautiously with prior methods.

Diagnostic strategy#

Obtain decision-linked testing now#

Because of symptomatic hypotension, reduced urine, and interacting discrepancies, the team obtains an urgent basic metabolic panel. The panel includes creatinine, sodium, and potassium, with magnesium as clinically appropriate. A 12-lead ECG assesses rhythm, conduction, ischemic change, and manifestations that may accompany severe potassium disturbance. Complete blood count, urinalysis, cardiac biomarkers, imaging, or infection studies are added only when the presentation supports those branches.

The discharge creatinine, estimated filtration rate, and potassium are the comparison baseline. So are sodium, blood pressure, weight, and volume examination. A single new creatinine value is interpreted as a change from that baseline and alongside perfusion and congestion. Natriuretic peptide testing is not a substitute for examination and reconciliation; levels can remain elevated and are influenced by age, kidney function, rhythm, body composition, and treatment.

Decide the site of care before optimizing long-term therapy#

Persistent symptomatic hypotension, severe or rising potassium abnormality, or substantial acute kidney change warrants emergency or hospital-level evaluation. So does oliguria, syncope, or new ECG abnormality. So do ischemic symptoms, respiratory distress, or hypoxemia. So does confusion or uncertain home safety. Stable patients with mild abnormalities may sometimes be managed through same-day specialty and laboratory follow-up, but only when the team can act promptly and the patient can reliably follow the plan.

Medication optimization comes after immediate stability. The question is not simply whether each class is guideline supported; it is whether this patient can safely receive the intended combination today and what monitoring each change requires.

Progressive results and interpretation#

Laboratory testing shows potassium 5.8 mmol/L and creatinine 1.7 mg/dL, increased from 1.1 mg/dL at discharge. Sodium is mildly low. The ECG shows sinus rhythm without a classic potassium-related conduction pattern. Absence of ECG change does not make the potassium value benign, especially with an acute rise, kidney dysfunction, and continued use of several contributing medicines.

The clinic weight is 1.2 kilograms below the recorded discharge weight. Repeat examination still shows clear lungs, no edema, low jugular venous pressure, and symptomatic standing hypotension. These findings favor low effective volume and medication effect over recurrent congestion, while acknowledging that no bedside sign is perfect.

The hospital pharmacist confirms that the prior angiotensin-converting enzyme inhibitor was intended to stop before the angiotensin receptor-neprilysin inhibitor began and should not have remained on the final list. The potassium supplement was also meant to stop. The loop-diuretic frequency was supposed to be reassessed promptly after discharge, but two versions of the instructions were released.

The combined findings represent a high-risk adverse transition: symptomatic hypotension, acute kidney dysfunction, and hyperkalemia in the setting of unintended duplicate therapy, potassium supplementation, continued anti-inflammatory use, poor intake, and a likely excessive diuretic effect. A normal oxygen saturation and improved breathing do not make outpatient delay safe. The patient is transferred for monitored same-day treatment and medication correction.

Management plan#

Address the acute safety problem#

At the receiving site, the team confirms the laboratory results, monitors rhythm and perfusion, evaluates volume status and urine output, and treats hyperkalemia and hypotension according to severity and local protocols. Exact emergency treatments and doses are omitted because they depend on the ECG, repeated potassium, and kidney function. They depend on volume state, glucose, comorbidities, and response.

The unintended overlapping renin-angiotensin therapies and potassium supplement are stopped under clinician direction. The anti-inflammatory medicine is discontinued and a safer pain strategy is planned. Diuretic and other heart-failure medicines are reassessed rather than blindly continued or permanently abandoned. Volume correction is cautious because indiscriminate fluid can worsen heart failure, while continued diuresis can worsen low perfusion.

Rebuild one intended regimen#

After stabilization, cardiology, primary care, and pharmacy construct one list with the patient and her daughter. Every line has an indication and one of four explicit actions: continue, start, change, or stop. The list distinguishes disease-modifying therapy from symptom-directed diuresis and explains which medicines require laboratory monitoring. Obsolete orders are discontinued in the hospital, clinic, and pharmacy systems; duplicate bottles are removed with permission; and the community pharmacy receives the final list directly.

For HFrEF, contemporary guidance supports using the major evidence-based medication classes in eligible patients and optimizing them without unnecessary delay. Eligibility and sequencing still depend on hemodynamic stability, kidney function, and potassium. They depend on congestion, prior intolerance, drug interactions, and access. The goal is not to earn credit for four classes on a list; it is to deliver a tolerated regimen with monitoring and continued titration.

The plan specifically avoids simultaneous use of an angiotensin-converting enzyme inhibitor and an angiotensin receptor-neprilysin inhibitor. Required separation between those therapies and history of angioedema must be checked. Mineralocorticoid receptor antagonists require acceptable kidney function and potassium at initiation and close follow-up. Beta blockers are managed in the context of clinical stability, heart rate, blood pressure, and congestion. Sodium-glucose cotransporter-2 inhibitors require attention to volume status, genitourinary adverse effects, and temporary interruption in selected acute illness or prolonged fasting situations under clinician guidance. Loop-diuretic intensity follows congestion and response rather than serving as a fixed marker of disease-modifying success.

No individualized dose appears in this educational case. Each change follows the current guideline, product information, and responsible clinician's assessment.

Tie monitoring to the medicine and risk#

Before initiation or intensification, the team documents blood pressure, volume status, and creatinine or estimated filtration rate. It documents sodium and potassium when relevant. After a mineralocorticoid receptor antagonist is started or increased, contemporary cardiology guidance calls for close potassium and kidney-function monitoring, commonly at about one week and again around four weeks, then periodically if stable; higher-risk physiology requires earlier checks. KDIGO advises checking blood pressure, creatinine, and potassium within two to four weeks of initiating or increasing a renin-angiotensin system inhibitor, with timing shortened when filtration or potassium makes risk higher.

This patient's recent hyperkalemia, acute kidney change, and post-discharge instability require monitoring sooner than a routine interval. The final plan writes the actual dates, location, tests, result recipient, and action thresholds. "Labs next week" is not a plan. Any new diuretic change also prompts a defined reassessment of weight, symptoms, and blood pressure. The reassessment covers kidney function, sodium, potassium, and magnesium as appropriate.

Complete the transition bundle#

Before the next discharge, the patient is clinically stable on an oral regimen, has a volume and laboratory plan, and has an early follow-up appointment. The 2022 AHA/ACC/HFSA guideline describes early follow-up, generally within seven days after worsening-heart-failure hospitalization, as reasonable. A shorter interval is used when risk demands it.

The discharge packet includes the diagnosis and ejection fraction, precipitating factors, and the final medicine list with changes and reasons. It includes pending tests, the monitoring schedule, and the weight and symptom plan. It includes dietary and activity guidance individualized to the patient, rehabilitation or disease-management referrals when appropriate, emergency thresholds, and direct contacts. A clinician-to-clinician handoff accompanies patient education.

Escalation, referral, and safety net#

Emergency assessment is warranted for fainting, severe or persistent hypotension, or confusion. It is warranted for chest pressure, new severe breathlessness, or blue or gray color. It is warranted for rapid worsening edema with respiratory symptoms, very low urine output, or new sustained palpitations. It is warranted for significant bleeding or a laboratory alert for dangerous potassium or kidney change. The patient should not take extra diuretic, potassium, or an old discontinued medicine on her own unless the written clinician-authored plan specifically directs that action.

Same-day contact is appropriate for rapidly changing weight accompanied by symptoms, increasing orthopnea, or new swelling. It is appropriate for dizziness, poor intake, or vomiting or diarrhea. It is appropriate for medication errors, inability to obtain a prescription, or uncertainty after a pharmacy substitution. A weight threshold without symptom and response instructions is incomplete.

Heart-failure specialty input is appropriate for recurrent hospitalization, persistent intolerance that blocks evidence-based therapy, or uncertain volume state. It is appropriate for advanced symptoms, device-therapy questions, or consideration of advanced and palliative approaches. Nephrology input may be needed for progressive kidney dysfunction, recurrent potassium problems, or difficult cardiorenal tradeoffs. Clinical pharmacy is not an optional afterthought in a transition with multiple discrepancies.

Communication, shared decisions, and equity#

The clinician tells the patient, "You followed two lists that disagreed. The system gave you unsafe instructions; this is not your fault." That framing invites accurate disclosure and avoids hiding the system defect behind a label of nonadherence.

Teach-back asks the patient to use the final list and bottles to show what she will take tomorrow, what has stopped, when the laboratory visit occurs, and which symptoms trigger a call or emergency help. Large print, good lighting, face-to-face speech, and hearing support address communication access. Color alone is not used to distinguish medicines. The daughter participates only with the patient's permission, and the plan preserves the patient's own decision-making role.

Cost and formulary barriers are checked before discharge because an unaffordable four-class plan becomes no plan. The team aligns refill dates, considers packaging support, confirms transportation to the laboratory and visit, and ensures the patient has an accurate scale on a hard surface. Food access, caregiving, and health literacy change what can safely be monitored at home. So do language, pharmacy hours, and digital access.

Shared decision-making includes benefits, adverse effects, monitoring burden, symptom priorities, and the patient's goals. It does not convert a dangerous duplicate or unmonitored potassium risk into a preference-neutral option.

Follow-up and contingencies#

The first follow-up after stabilization reviews the actual bottles and list again. It reviews symptoms, orthopnea, and edema. It reviews appetite, urine, dizziness, and falls. It reviews home weight technique and trend, and seated and standing blood pressure when indicated. It reviews heart rate, volume examination, and kidney function. It reviews sodium, potassium, and adverse effects. The clinician verifies that the pharmacy, cardiology office, primary-care record, and patient copy agree.

Thereafter, titration proceeds in small, monitored steps toward a tolerated evidence-based regimen. Each adjustment has a reason, a laboratory or vital-sign plan, and a named responder. Persistent congestion may require diuretic adjustment and investigation of precipitating factors. Recurrent low pressure without congestion prompts review of volume, timing, interacting medicines, autonomic symptoms, and which agents provide the most benefit. A modest expected filtration change is distinguished from progressive injury, symptomatic hypotension, uncontrolled hyperkalemia, or another acute cause.

If creatinine and potassium recover, disease-modifying medicines are reconsidered systematically rather than permanently omitted because of one transition error. If potassium repeatedly rises, the team reviews kidney function, diet and salt substitutes, and supplements. It reviews interacting medicines and guideline-supported mitigation strategies with specialists. If symptoms worsen despite apparent adherence, the diagnosis, rhythm, and ischemia are reassessed. So are valvular disease and the advanced-heart-failure trajectory.

The health system also performs a safety review: why two incompatible lists printed, why discontinuations failed to reach the pharmacy, why no laboratory owner was assigned, and how to prevent recurrence. Fixing this patient's pillbox without fixing the transition leaves the next patient exposed.

Reasoning traps and alternative pathways#

• Treating the discharge list as ground truth: It may contain copied, stale, or internally conflicting orders.
• Calling reconciliation data entry: The task is to resolve intent and actual use, communicate the result, and verify that every destination agrees.
• Assuming all post-discharge breathlessness or weakness is congestion: Overdiuresis, hypotension, kidney injury, electrolyte disturbance, infection, anemia, and rhythm problems may look similar.
• Reacting to creatinine without volume context: Both ignoring a major rise and reflexively stopping beneficial therapy can cause harm.
• Optimizing the medication score before stability: Guideline-supported classes still require safe hemodynamics, kidney function, potassium, and monitoring.
• Using a normal ECG to dismiss hyperkalemia: ECG sensitivity is incomplete; the result, trajectory, and clinical setting matter.
• Giving generic salt, fluid, or weight instructions: The safe plan depends on congestion, kidney function, sodium, blood pressure, and the individual's circumstances.
• Leaving follow-up passive: A laboratory order without date, transportation, result owner, and response threshold is an open loop.
• Blaming the patient for duplication: Conflicting printouts, pharmacy messages, bottle labels, and clinician records are system evidence.

An alternative pathway would prioritize congestion if orthopnea, edema, jugular venous pressure, pulmonary findings, and weight were rising. Chest pain or ischemic ECG change would activate an acute coronary pathway. Sustained arrhythmia, infection, bleeding, or pulmonary embolism would redirect testing and treatment. Cardiogenic shock features would require immediate critical care rather than routine reconciliation.

Evidence limits and what could change#

Heart-failure guidelines support early and comprehensive disease-modifying therapy, but trial populations and consensus pathways do not eliminate bedside heterogeneity. Ejection fraction phenotype, blood pressure, and kidney function change eligibility and sequence. So do potassium, frailty, and rhythm. So do valvular disease, ischemia, comorbidity, and patient goals. Monitoring intervals differ among drug classes, product labels, guidelines, and risk states; high-risk patients need earlier surveillance than a generic calendar suggests.

Creatinine may rise from hemodynamic effects, decongestion, or low perfusion. It may rise from obstruction, nephrotoxins, or intrinsic kidney disease. Physical signs and home weights are imperfect. The clinician therefore uses trends and converging evidence rather than a single number. Medication-reconciliation programs reduce discrepancies variably because effectiveness depends on staffing, information flow, and actual follow-through.

A new 2026 or later heart-failure update, revised product labeling, a different ejection fraction, recurrent hyperkalemia, or the patient's goals could change this plan. This high-risk case has completed human review by Jasaman (Jasmin) Tojjar, MD, PhD.

Key points#

• Compare the preadmission list, inpatient record, discharge intent, pharmacy data, bottles, and actual use; no single source is automatically correct.
• Post-discharge dizziness and kidney change require simultaneous assessment of volume, pressure, potassium, medicines, and acute alternatives.
• Evidence-based HFrEF therapy is a monitored clinical process, not a checklist copied into the chart.
• Every medicine change needs an indication, interaction check, laboratory plan, follow-up date, and named owner.
• Teach-back should demonstrate what the patient will actually do with the bottles, not merely repeat that instructions were understood.
• A safe transition closes loops across patient, caregiver, hospital, clinic, laboratory, pharmacy, and specialists, and investigates the system failure when those loops break.